AI assistant
UCB — Share Issue/Capital Change 2020
Mar 2, 2020
4017_dirs_2020-03-02_561faff3-6b2f-4030-9214-4b56f7c6671e.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Disposal of own shares
Brussels (Belgium), 2 March 2020 – 20:00 (CET) – regulated information
In application of article 8:6 of the Royal Decree executing the new Belgian Code of Companies and Associations, UCB SA/NV announces that following exercises of stock options by its employees, it has disposed of UCB shares OTC in view of deliveries of shares to the relevant employees, within the framework of the Long Term Incentive Program of the UCB Group, as follows:
| Date of transaction | Time | LTI Plan | Number of disposed UCB shares |
Price |
|---|---|---|---|---|
| 21 February 2020 | 09:01:07 | Stock Option Plan 2015 | 2,400 | 67.35 |
| 21 February 2020 | 09:01:17 | Stock Option Plan 2016 | 2,006 | 67.24 |
| 21 February 2020 | 09:22:35 | Stock Option Plan 2010 | 800 | 31.62 |
| 21 February 2020 | 09:32:44 | Stock Option Plan 2011 | 1,000 | 26.72 |
| 21 February 2020 | 09:36:37 | Stock Option Plan 2016 | 2,300 | 67.24 |
| 21 February 2020 | 10:08:33 | Stock Option Plan 2015 | 600 | 67.35 |
| 21 February 2020 | 10:13:08 | Stock Option Plan 2016 | 1,000 | 67.24 |
| 21 February 2020 | 10:53:42 | Stock Option Plan 2011 | 900 | 26.72 |
| 21 February 2020 | 11:31:44 | Stock Option Plan 2016 | 700 | 67.24 |
| 21 February 2020 | 11:41:42 | Stock Option Plan 2013 | 2,600 | 48.69 |
| 21 February 2020 | 11:51:41 | Stock Option Plan 2013 | 300 | 48.69 |
| 21 February 2020 | 12:15:41 | Stock Option Plan 2012 | 1,000 | 32.36 |
| 21 February 2020 | 13:06:38 | Stock Option Plan 2016 | 1,000 | 67.24 |
| 21 February 2020 | 13:22:57 | Stock Option Plan 2010 | 2,900 | 31.62 |
| 21 February 2020 | 14:57:15 | Stock Option Plan 2012 | 500 | 32.36 |
| 21 February 2020 | 16:49:17 | Stock Option Plan 2015 | 1,500 | 67.35 |
| 21 February 2020 | 17:14:30 | Stock Option Plan 2016 | 200 | 67.24 |
| 21 February 2020 | 17:18:23 | Stock Option Plan 2012 | 1,000 | 32.36 |
| 21 February 2020 | 17:25:09 | Stock Option Plan 2013 | 136 | 49.8 |
| 24 February 2020 | 10:10:52 | Stock Option Plan 2014 | 576 | 58.12 |
| 24 February 2020 | 10:43:54 | Stock Option Plan 2016 | 400 | 67.24 |
| 24 February 2020 | 10:58:01 | Stock Option Plan 2013 | 200 | 48.69 |
| 24 February 2020 | 12:52:48 | Stock Option Plan 2014 | 500 | 58.12 |
| 24 February 2020 | 12:55:24 | Stock Option Plan 2013 | 300 | 48.69 |
| 24 February 2020 | 13:26:06 | Stock Option Plan 2016 | 2,000 | 67.24 |
| 24 February 2020 | 13:28:48 | Stock Option Plan 2015 | 2,000 | 67.35 |
| 25 February 2020 | 09:00:36 | Stock Option Plan 2014 | 500 | 58.12 |
| 25 February 2020 | 09:00:46 | Stock Option Plan 2016 | 100 | 67.24 |
|---|---|---|---|---|
| 25 February 2020 | 09:00:56 | Stock Option Plan 2011 | 500 | 26.72 |
| 25 February 2020 | 09:01:42 | Stock Option Plan 2016 | 1,500 | 67.24 |
| 25 February 2020 | 15:19:32 | Stock Option Plan 2013 | 500 | 48.69 |
| 25 February 2020 | 16:39:58 | Stock Option Plan 2015 | 1,350 | 67.35 |
| 26 February 2020 | 14:38:50 | Stock Option Plan 2011 | 100 | 26.72 |
| 26 February 2020 | 15:30:12 | Stock Option Plan 2011 | 50 | 26.72 |
| 26 February 2020 | 16:38:29 | Stock Option Plan 2012 | 800 | 32.36 |
| 26 February 2020 | 16:51:10 | Stock Option Plan 2012 | 2,500 | 32.36 |
| 26 February 2020 | 17:11:37 | Stock Option Plan 2016 | 500 | 67.24 |
| 26 February 2020 | 17:18:15 | Stock Option Plan 2016 | 200 | 67.24 |
| 27 February 2020 | 14:01:37 | Stock Option Plan 2012 | 700 | 32.36 |
| 27 February 2020 | 14:46:51 | Stock Option Plan 2010 | 2,500 | 31.62 |
| 27 February 2020 | 15:36:46 | Stock Option Plan 2016 | 931 | 67.24 |
This press release is available on UCB SA/NV's website via the following link.
Investor Relations
Antje Witte, Investor Relations, UCB T +32 2 559 94 14, [email protected]
Isabelle Ghellynck, Investor Relations, UCB T +32 2 559 95 88, [email protected]
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news